logo-loader

Smith & Nephew drops guidance as surgical procedures stop amid pandemic

Underlying revenue growth in the quarter to March is expected to drop 8% on 2019

Smith & Nephew

Smith & Nephew PLC (LON:SN.) has withdrawn guidance for 2020 as surgical procedures in the US and Europe are coming to a halt.

In China, which contributed more than half of group organic growth last year, hospital activity had restarted but remains “considerably below” pre-outbreak levels. 

READ: Analysts mull Smith & Nephew's big coronavirus assumptions

The medical products manufacturer said underlying revenue growth in the quarter to March is expected to drop 8% on 2019.

Second quarter revenue and first-half trading margin are estimated to come in “substantially down” compared to last year.

As of 31 December, net debt was US$1.6bn, with committed facilities of US$2.9bn plus another US$550mln in senior notes to be drawn in June.

Shares dropped 3% to 1,389.5p on Monday morning.

--Adds shares--

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

1 day ago

2 min read